CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleLevered free cash flow is $74.59M, above the global median of $16.24M
- PositionCurrent ratio is 0.64×, lower than 95% of its Medical Devices peers (median 3.83×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.10%Below 5Y avg (0.22%)
Annual Rate
KRW 50.00Paid annual
Payout Ratio
1.7%Sustainable
Last Ex-Dividend
Dec 29, 2025
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.28TKRW918.75M · vs all stocks (USD)
Revenue (TTM)
98.10BKRW70.69M · vs all stocks (USD)
Profit Margin
-137.76%vs Medical Devices peers
Beta
1.49xvs all stocks
52-Week Change
70.67%vs all stocks
Market Capitalization
1.28TKRW918.75M · vs all stocks (USD)
Enterprise Value
1.40TKRW1.01B · vs all stocks (USD)
Forward P/E
25.06xvs Medical Devices peers
Price to Sales (TTM)
13.57xvs Medical Devices peers
Price to Book (MRQ)
6.04xvs Medical Devices peers
Enterprise to Revenue
14.23xvs Medical Devices peers
Enterprise to EBITDA
77.45xvs Medical Devices peers
Gross Margin
60.57%vs Medical Devices peers
Profit Margin
-137.76%vs Medical Devices peers
Operating Margin
19.80%vs Medical Devices peers
Return on Assets (TTM)
1.33%vs Medical Devices peers
Return on Equity (TTM)
-53.40%vs Medical Devices peers
Revenue (TTM)
98.10BKRW70.69M · vs all stocks (USD)
Revenue per Share (TTM)
4.03KKRWUpdated Aug 19, 2026Quarterly Revenue Growth
71.40%vs Medical Devices peers
Gross Profit (TTM)
53.99BKRW38.90M · vs all stocks (USD)
EBITDA (TTM)
14.78BKRW10.65M · vs all stocks (USD)
Net Income (TTM)
-135.50BKRW-97.64M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
70.61%vs Medical Devices peers
Operating Cash Flow (TTM)
19.40BKRW13.98M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
103.52BKRW74.59M · vs all stocks (USD)
Trailing Annual Dividend Rate
50.00KRWUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.10%vs all stocks
5-Year Average Dividend Yield
0.22%vs all stocks
Payout Ratio
1.66%vs Medical Devices peers
Minority Interest (Equity)
10.31BKRWFY2025 · Dec 31, 2025Revenue
85.48BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
40.09BKRWFY2025 · Dec 31, 2025Gross Profit
45.39BKRWFY2025 · Dec 31, 2025Operating Income
4.42BKRW3.18M · vs all stocks (USD)
Pre-tax Income
-160.03BKRWFY2025 · Dec 31, 2025Income Tax Expense
-21.68BKRWFY2025 · Dec 31, 2025Net Income
-138.25BKRWFY2025 · Dec 31, 2025EBIT
-154.17BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
14.78BKRWFY2025 · Dec 31, 2025Research & Development
4.10BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
22.91BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
1.31BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
5.87BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-138.25BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
71.99MKRWFY2025 · Dec 31, 2025Operating Cash Flow
-132.55BKRWFY2025 · Dec 31, 2025Free Cash Flow
-148.36BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
30.89BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-138.25BKRWFY2025 · Dec 31, 2025Stock-based Compensation
270.63MKRWFY2025 · Dec 31, 2025Other Non-cash Items
4.64BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.15BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
3.93BKRWFY2025 · Dec 31, 2025Capital Expenditures
-15.81BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.23BKRWFY2025 · Dec 31, 2025Net Acquisitions
-14.33BKRWFY2025 · Dec 31, 2025Purchase of Investments
-125.00BKRWFY2025 · Dec 31, 2025Sale of Investments
121.87BKRWFY2025 · Dec 31, 2025Other Investing Activity
237.37MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-33.03BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
70.22BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-46.63BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-13.76BKRWFY2025 · Dec 31, 2025Common Stock Repurchase
-10.02BKRWFY2025 · Dec 31, 2025Common Dividends Paid
-1.12BKRWFY2025 · Dec 31, 2025Other Financing Charges
1.33BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
17.33BKRWFY2025 · Dec 31, 2025Shares Outstanding
24.61MSharesUpdated Aug 19, 2026Float Shares
16.54MSharesUpdated Aug 19, 2026% Held by Insiders
24.52%vs all stocks
% Held by Institutions
16.09%vs all stocks
Total Cash (MRQ)
48.64BKRW35.05M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.98KKRWUpdated Aug 19, 2026Total Debt (MRQ)
87.49BKRW63.04M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4103xvs Medical Devices peers
Current Ratio (MRQ)
0.6360xvs Medical Devices peers
Book Value per Share (MRQ)
8.58KKRWUpdated Aug 19, 2026Total Assets
456.64BKRW329.03M · vs all stocks (USD)
Total Current Assets
139.19BKRWFY2025 · Dec 31, 2025Total Liabilities
248.10BKRWFY2025 · Dec 31, 2025Total Non-current Assets
317.45BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
10.31BKRWFY2025 · Dec 31, 2025Total Current Liabilities
237.80BKRWFY2025 · Dec 31, 2025Cash Equivalents
30.89BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
30.89BKRWFY2025 · Dec 31, 2025Other Short-term Investments
5.93BKRWFY2025 · Dec 31, 2025Accounts Receivable
24.72BKRWFY2025 · Dec 31, 2025Inventory
42.82BKRWFY2025 · Dec 31, 2025Accounts Payable
1.40BKRWFY2025 · Dec 31, 2025Short-term Debt
83.95BKRWFY2025 · Dec 31, 2025Other Current Liabilities
1.30BKRWFY2025 · Dec 31, 2025Long-term Debt
8.25BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
410.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
12.36BKRWFY2025 · Dec 31, 2025Retained Earnings
99.34BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
208.53BKRW150.26M · vs all stocks (USD)
Treasury Stock
8.30BKRWFY2025 · Dec 31, 202552-Week Low
29.15KKRWUpdated Aug 19, 202652-Week High
125.00KKRWUpdated Aug 19, 202652-Week Change
70.67%vs all stocks
Beta
1.49xvs all stocks
50-Day MA
72.20KKRWUpdated Aug 19, 2026200-Day MA
70.30KKRWUpdated Aug 19, 2026Avg 10-Day Volume
267.79KSharesUpdated Aug 19, 2026Avg 30-Day Volume
268.07KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-5.81KKRWUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.64×, lower than 95% of its Medical Devices peers (median 3.83×)Significant
Current ratio: 0.64Industry median: 3.83Industry P5: 1.47Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.61Profit Margin: -1.38
Financial Health
Altman Z-Score 2.2: grey zoneSignificant
Altman Z-Score: 2.20
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Levered free cash flow is $74.59M, above the global median of $16.24MNotable
Levered free cash flow (USD): 74,589,108.412Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Pharma Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jiudian Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing SL Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Geron Corporation
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Huakang Century Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Keqian Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou Biotest Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Isotope & Radiation Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Wit Dyne Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shandong Longda Meishi Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated